Edition:
United States

AMAG Pharmaceuticals Inc (AMAG.OQ)

AMAG.OQ on NASDAQ Stock Exchange Global Select Market

14.80USD
3:59pm EST
Change (% chg)

$0.45 (+3.14%)
Prev Close
$14.35
Open
$14.25
Day's High
$14.93
Day's Low
$14.25
Volume
192,678
Avg. Vol
204,995
52-wk High
$25.15
52-wk Low
$11.93

Latest Key Developments (Source: Significant Developments)

AMAG Pharmaceuticals Sees Q4 2017 Revenue $156 Mln to $163 Mln
Monday, 8 Jan 2018 08:00am EST 

Jan 8 (Reuters) - AMAG Pharmaceuticals Inc ::AMAG PHARMACEUTICALS ANNOUNCES PRELIMINARY 2017 FINANCIAL RESULTS AND PROVIDES 2018 GUIDANCE.SEES Q4 2017 REVENUE $156 MILLION TO $163 MILLION.SEES FY 2017 REVENUE $613 MILLION TO $620 MILLION.SEES FY 2017 REVENUE UP 15 PERCENT.SEES Q4 2017 REVENUE UP ABOUT 5 PERCENT.- ‍FOR Q4 OF 2017, AMAG EXPECTS AN OPERATING LOSS OF BETWEEN $6 MILLION AND $16 MILLION​.- ‍EXPECTS 2017 TOTAL GAAP REVENUE TO BE BETWEEN $607 MILLION AND $614 MILLION​.SEES ‍ 2017 OPERATING LOSS OF BETWEEN $292 MILLION AND $302 MILLION (DUE PRIMARILY TO A Q3 NON-CASH ACCOUNTING CHARGE)​.SEES ‍2018 TOTAL GAAP REVENUE $500 MILLION - $560 MILLION​.SEES ‍2018 GAAP OPERATING LOSS $147 MILLION - $117 MILLION​.Q4 REVENUE VIEW $161.1 MILLION -- THOMSON REUTERS I/B/E/S.FY2017 REVENUE VIEW $616.0 MILLION -- THOMSON REUTERS I/B/E/S.FY2018 REVENUE VIEW $504.1 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Palatin Technologies signs licensing agreement with Kwangdong Pharma
Tuesday, 21 Nov 2017 07:30am EST 

Nov 21 (Reuters) - Palatin Technologies :Palatin Technologies announces signing of licensing agreement with Kwangdong Pharmaceutical for Republic of Korea.A NDA anticipated to be filed with U.S. Food and Drug Administration in Q1 of calendar year 2018​.  Full Article

Amag Pharmaceuticals Q3 loss per share $4.31
Thursday, 2 Nov 2017 07:00am EDT 

Nov 2 (Reuters) - Amag Pharmaceuticals Inc :Amag Pharmaceuticals announces third quarter 2017 financial results and business highlights.Q3 loss per share $4.31.Q3 earnings per share view $0.18 -- Thomson Reuters I/B/E/S.Q3 revenue $153.7 million versus I/B/E/S view $168.5 million.Amag Pharmaceuticals Inc - ‍co has updated 2017 Makena revenue guidance to between $385 million and $395 million​.  Full Article

Amag Pharmaceuticals announces U.S. FDA filing acceptance
Thursday, 31 Aug 2017 08:00am EDT 

Aug 31 (Reuters) - Amag Pharmaceuticals Inc ::Amag announces U.S. FDA filing acceptance and six-month review of Feraheme® (Ferumoxytol) for the treatment of all adult patients with iron deficiency anemia.Amag Pharmaceuticals Inc - ‍prescription drug user fee act target action date of February 2, 2018 for feraheme​.  Full Article

Amag Pharmaceuticals Q2 loss per share $0.40
Thursday, 3 Aug 2017 07:02am EDT 

Aug 3 (Reuters) - Amag Pharmaceuticals Inc ::Amag pharmaceuticals announces second quarter 2017 financial results and provides corporate update.Q2 loss per share $0.40.Q2 earnings per share view $1.34 -- Thomson Reuters I/B/E/S.Q2 revenue $158.4 million versus I/B/E/S view $158.6 million.Amag pharmaceuticals inc - ‍reaffirming 2017 financial guidance​.Amag pharmaceuticals inc - sees ‍ 2017 GAAP total revenue $625 million - $685​ million.  Full Article

Amag completes feraheme FDA submission for the treatment of all adult patients with iron deficiency anemia
Thursday, 3 Aug 2017 07:00am EDT 

Aug 3 (Reuters) - Amag Pharmaceuticals Inc :Amag completes Feraheme® (ferumoxytol) FDA submission for the treatment of all adult patients with iron deficiency anemia.Amag Pharmaceuticals Inc - ‍Potential approval and launch in first half of 2018 for feraheme​.  Full Article

Amag reports U.S. FDA acceptance of supplemental new drug application for Makena
Monday, 26 Jun 2017 08:00am EDT 

June 26 (Reuters) - Amag Pharmaceuticals Inc ::Amag announces U.S. FDA filing acceptance of supplemental new drug application for makena® (hydroxyprogesterone caproate injection) subcutaneous auto-injector.Amag Pharmaceuticals Inc - prescription drug user fee act (pdufa) target action date of february 14, 2018.Amag Pharmaceuticals Inc - FDA has now determined that filing is subject to a standard 10-month review.Amag Pharmaceuticals Inc - if makena auto-injector is approved, amag will request orange book listing of eligible antares patents, last of which expires in 2026.Amag Pharmaceuticals Inc - ‍reaffirming 2017 financial guidance, including makena revenue guidance of $410 million to $440 million​.  Full Article

Camber Capital Management LLC reports 7.13 pct passive stake in AMAG Pharmaceuticals
Monday, 15 May 2017 12:38pm EDT 

May 15 (Reuters) - AMAG Pharmaceuticals Inc ::Camber Capital Management LLC reports 7.13 percent passive stake in AMAG Pharmaceuticals Inc as on May 04, 2017 - SEC filing.  Full Article

Amag Pharmaceuticals Inc says increased size of offering to $300 mln
Friday, 5 May 2017 07:00am EDT 

May 5 (Reuters) - Amag Pharmaceuticals Inc :Amag Pharmaceuticals announces pricing of $300 million of 3.25% convertible senior notes due 2022.Amag Pharmaceuticals Inc- amag has increased size of offering from originally announced $250 million.  Full Article

AMAG Pharma announces proposed offering of $250 mln of convertible senior notes due 2022
Wednesday, 3 May 2017 04:17pm EDT 

May 3 (Reuters) - AMAG Pharmaceuticals Inc :AMAG Pharmaceuticals Inc announces proposed offering of $250 million of convertible senior notes due 2022.AMAG Pharmaceuticals Inc says notes will pay interest semiannually and will mature on june 1, 2022.AMAG Pharmaceuticals Inc -intends to use net proceeds from offering of notes together with cash on hand to repay approximately $320.8 million of borrowings.AMAG Pharmaceuticals Inc says may enter into privately negotiated transactions with certain holders of its existing 2.50% convertible senior notes due 2019.  Full Article

BRIEF-AMAG Pharmaceuticals Sees Q4 2017 Revenue $156 Mln to $163 Mln

* AMAG PHARMACEUTICALS ANNOUNCES PRELIMINARY 2017 FINANCIAL RESULTS AND PROVIDES 2018 GUIDANCE